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Smy Results from a long-term follow-up suggest that in patients with Emited smal-cell lung cancer
(SCLC) and normal performance status ints alternatig chemotherapy and radiotherapy Improve long-
term survival rates. In a non-ranmised study, 22 patints with SCLC of inited extent and good perform-
ance status were prescnibed six cyces of etoposide, doxorubcin, cisplatin and cydophosphamide at 4 week
intervals with doses of thoracic radiotherapy foowing the second, third and fourth cydes Although only six
patients recevd all thei ed treatment, nie (41%) were aie at 1 year, seven (32%) at 2 years, six
(27%) at 3 years, and four are still alive at, respecly, 42, 47, 50, and 61 months, all four being in the
subgroup of eight patiets with WHO performance status grade 0 at the start of treatment. In a comparison
with similar patients recdving conventionally shedulkd chemotherapy and radiotherapy in a concurrent trial,
no difference in survival was see in the patients with performance status grade I or 2, but a lare difference in
favour of the alternating schedule in those with grade 0 status was seen. We encourage other investigators to
report the results achieved with intensive treatment in patients with WHO grade 0 performance status at the
start of treatment.
Although standard combination chemotherapy and thorac
radiotherapy regimens prolong survival in patients with
SCLC of limited extent, long-term survival rates are low. The
purpose of the present paper is to draw attention to the
numbers and characterstics of long-term survivors treated
with a highly intensive regimen of alternating chemotherapy
and radiotherapy.
During 1988 and 1989, the Medical Research Council
(MRC) Lung Cancer Working Party conducted a non-
randomised phase H study of six cycles of etoposide,
doxorubicin, cisplatin and cyclophosphamide, at 4 week
intervals, alternating with three courses of thoracic radio-
therapy given after the second, third and fourth cycles of
chemotherapy, in the treatment of SCLC of limited extent
(Bleehen et al., 1991). Arriagada and his colleagu, usng
this altemating scheduling, reported high reponse rates and
2 year and 3 year survival rates substantially higher than are
usually achieved, suggesting that alternating scheduling might
improve long-term survival rates (Le Chevalier et al., 1987;
Ariagada et al., 1990).
The original purpose ofour study was to determine wheth-
er the regimen used by Arriagada and his collagues was
Iogistically feasible in centres in the UK, whether the toxicity
is acceptable, and whether a high complete response rate
could be confirmed, with a view to then considering a
multicentre randomised trial comparing alternating versus
conventional scheduling. In the event, the working party
concluded that the alternating regimen was logistilly feas-
ible in only a small proportion ofcentres in the UK and that
the level of toxicity was in excess of that tolerated by most
patients. However, comparison of patients in the present
study with patients with similar extent of disease and
performance status, treated with conventionally scheduled
chemotherapy and radiotherapy in a concurrent MRC triaL
suggests that the long-term survival rates could be increased
with intensive treatment.
Patid;ts ad mthod
The methods were presented in detail in the first report. In
summary, the patients had previously untreated SCLC of
limited extent and good performance status (grade 0-2,
World Health Organization, 1979).
They were all prescribed six cycles of chemotherapy, to be
given during five consecutive days at 4 week intervals, and
three courses of radiotherapy following the second, third and
fourth cycles of chemotherapy.
The chemotherapy consisted of etoposide 75 mgm2 given
by i.v. infusion on days 1, 2 and 3; doxorubicin 40mg m-2
by i.v. injection on day 1; isplatin lOOmgm-2 by i.v. injec-
tion on day 2; and cyclophosphamide 300mgm2 by i.v.
injection on days 2, 3, 4 and 5. After 12 patients had been
admitted, the cisplatin dosage was reduced to 80 mg m-2
because of excessive toxicity.
Radiotherapy was given using planned fields to all visible
tumour with a 1.5 cm margin, as well as to the mediastinum,
both lung hila and supraclavicular regions. It was given in
fractions of 2 Gy five times per week; 20 Gy following the
second and third cycles of chemotherapy and 15 Gy follow-
ing the fourth cycle (total dose 55 Gy). The first two doses
were given through opposed anteroposterior fields, the third
through lateral fields avoiding the spinal cord.
The Kaplan-Meier estimate was used to caculate survival
curves and the Mantel-Cox version of the log-rank test to
make group comparisons. Survival was calculated from the
date of start of chemotherapy.
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Rests
Patients in the study
Between June 1988 and November 1989, 22 patients with
confirmed SCLC were admitted to the study.
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Long-term follow-up
At the time of the previous report, only four patients had
died. Since then, the patients have been followed up for an
additional 3 years, during which time 14 more have died. The
updated survival data are shown in Table I and Figure 1.
Table I also shows, for each patient, the performance status,
the treatment actually received and, where relevant, the
reason why treatment was not completed. Nine (41%) of the
22 patients were alive at 1 year, seven (32%) at 2 years and
six (27%) at 3 years. Two of the 14 patients (nos. 13 and 14)
who died during the follow-up died of causes unrelated to
cancer, and one other (no. 2) of non-small cell lung cancer in
the opposite lung. Four patients are still alive at the time of
this analysis. Of the six patients who received all six cycles of
chemotherapy and all three of radiotherapy, one died after
325 days (11 months), one after 554 (18 months) and one
after 1,295 (43 months). The remaining three are still alive at
1,274, 1,440, and 1,867 days (42, 47 and 61 months).
Also included in Figure 1 is the survival curve for a similar
group of patients being treated in a concurrent trial with a
conventionally scheduled regimen, namely 215 eligible
patients with limited disease and performance status ofWHO
grade 0, 1 or 2 on admission in a multicentre randomised
MRC trial who started treatment with three or six cycles of
etoposide, cvclophosphamide, methotrexate and vincristine or
six cycles of etoposide and ifosfamide plus thoracic
radiotherapy conventionally scheduled (MRC Lung Cancer
Working Party, 1993). All were followed up for at least 4
years. Although this is not a randomised comparison, it
suggests an advantage to the alternating regimen. Thus, the
survival rates in the conventionally treated group are 14% at
2 years and 9% at 3 years, compared with 32% and 27%,
respectively, for the patients treated with the alternating
regimen. In Figure 2, however, the same results are shown
but with the patients divided according to their performance
status. The survival curves (upper part of figure) for the 14
patients in the present study and the 163 in the conven-
tionally treated group with a performance status of grade 1
or 2 are clearly very similar (hazard ratio 1.03; 95%
confidence interval 0.59-1.80). In marked contrast, those for
the eight patients from the present study and 52 from the
conventionally treated group with a performance status of
grade 0 strongly suggest that with the intensive alternating
regimen the long-term survival rate was higher (hazard ratio
0.38, 95% confidence interval 0.19-0.78).
Discon
We are aware of the difficulties inherent in subgroup
analyses, particularly in non-randomised compansons involv-
ing small patient numbers. Nevertheless, there is a strong
suggestion from the present long-term follow-up that there is
a real benefit from the alternating scheduling, but that it may
be confined to the small subgroup of patients with WHO
performance status of grade 0 at the time treatment is
started. Indeed, all four of the patients still alive 1,274 days
(42 months) or more after the start of treatment came from
this subgroup, these being four of the total of eight in this
subgroup.












Fgwe 1 Survival from date of start of treatment for all 22
patients in the present study ( ) compared with the 215
patients with limited disease and performance status of WHO
grade 0, 1 or 2 in a concurrent multicentre randomised MRC
trial ( ) involving conventionally scheduled chemotherapy and
radiotherapy.
TableI Characteristicsofthe22patientswithconfirmed SCLCandtheresultsoftreatment. Thepatientsareranked
according to the amount ofchemotherapy (CT) and radiotherapy (RT) they received
Performance Number ofcourses
status on oftreatment Duration of
admission received survival Reason treatment
Patient (WHO grade) CT RT (days)' not completed Main cause ofdeath
Cisplatin 100 mgm-2
I 0 6 3 1,867+ -
2 0 5 3 1,598 Toxicity NSCLC in opposite lung
3 1 5 3 275 Toxicity Cancer
4 2 5 3 444 Toxicity Cancer
5 1 4 3 333 Toxicity Cancer
6 1 4 3 277 Toxicity Cancer
7 1 3 3 808 Toxicity Cancer
8 0 3 2 1,527 + Toxicity -
9 0 1 1 308 Progression Cancer
10 2 1 0 21 Death Bronchopneumonia
11 1 1 0 4 Death Sudden collapse
12 1 1 0 18 Death Bronchopneumonia
Cisplatin 80 mg m-'
13 1 6 3 1,295 - Unrelated, no cancer
14 1 6 3 554 - Pulmonary embolism
15 0 6 3 1,274 + -
16 0 6 3 1,440 + -
17 1 6 3 325 - Cancer
18 2 5 3 248 Toxicity Cancer
19 2 5 3 287 Toxicity Cancer
20 1 4 2 172 Progression Cancer
21 0 3 2 145 Progression Cancer
24 0 2 0 37 Death Sudden collapse












Concurrent trial 163 56 18 12 9











Concurrent trial 52 30 12 8 6
Present study 8 5 5 5 3
0 1 2 3 4
Years from start of treatment
Fge 2 a, Survival from date of start of treatment for the 14
patients with performance status of WHO grade I or 2 in the
present study (-) compared with the 163 similar patients with
performance status of WHO grade I or 2 in a concurrent mul-
ticentre randomised MRC trial ( ) involving conventionally
scheduled chemotherapy and radiotherapy. b, Corresponding
curves for the eight patients with performance status of WHO
grade 0 in the present study and the 52 with performance status
of WHO grade 0 in the randomised trial.
around 40% at 1 year, 30% at 2 years and 25% at 3 years
can be achieved when patients with SCLC of limited extent
and with good performance status are treated with an inten-
sive regimen of alternating chemotherapy and radiotherapy.
These findings confirm those of Arriagada and his colleagues,
who reported a survival rate of 26% at 3 years in a study of
109 patients (Le Chevalier et al., 1987), and of the Eastern
Cooperative Oncology Group, which reported a progression-
free survival rate of 33% at 3 years in a study of 34 patients
(Johnson et al., 1993).
Nevertheless, none of these phase II studies provides con-
clusive evidence of the superiority of alternating over conven-
tional scheduling. Indeed, these promising findings could be
the result of patient selection. The European Organization
for Research and Treatment of Cancer (EORTC) is currently
conducting a randomised trial with a planned intake of 360
patients in which a regimen of cyclophosphamide, doxo-
rubicin and etoposide plus thoracic radiotherapy is being
given either with conventional sequential scheduling, the
radiotherapy being given after completion of the five cycles
of chemotherapy, or with alternating scheduling (protocol
08877). As far as we are aware, this is the only randomised
trial that is making the important comparison of alternating
vs conventional scheduling. The results are therefore awaited
with great interest, although the chemotherapy is not as
intensive as that used in this study. It is also desirable that
other randomised trials investigate this comparison further.
In the present study, four of the patients died within 6
weeks of starting treatment, and treatment was considered a
contributory cause of death in all four (Bleehen et al., 1991).
This raises the possibility that the long-term results of
treating SCLC might be improved if ways could be found of
eliminating or greatly reducing the risk of early, treatment-
related death (Morritu et al., 1989; MRC Lung Cancer
Working Party, 1993).
We would urge other groups to report the results of inten-
sive treatment policies in patients with good performance
status. Other reports (reviewed by Johnson et al., 1993) have
not shown results separately for patients of different perfor-
mance status. It would be of great interest to see if similar
patterns of survival according to performance status are seen
in other studies. None, as far as we are aware, has been
analysed and presented in the way reported here.
Alternating chemotherapy and radiotherapy is logistically
demanding and carries a substantial risk of major toxicity,
but if it can offer even a small subgroup of patients a better
chance of cure it may be worth the risk.
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